Human Endoglin/CD105 Quantikine ELISA Kit
| Name | Human Endoglin/CD105 Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DNDG00 |
| Category | ELISA Kit |
| Prices | $519.00 |
| Sizes | 1 kit |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL) |
| Sensitivity | 0.03 ng/mL |
| Range | 0.2 - 10 ng/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human Endoglin Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human Endoglin in cell culture supernates, serum, and plasma |
| Gene | ENG |
| Supplier Page | Shop |
Product images
Product References
Association between Placental Lesions, Cytokines and Angiogenic Factors in - Association between Placental Lesions, Cytokines and Angiogenic Factors in
Weel IC, Baergen RN, Romao-Veiga M, Borges VT, Ribeiro VR, Witkin SS, Bannwart-Castro C, Peracoli JC, De Oliveira L, Peracoli MT. PLoS One. 2016 Jun 17;11(6):e0157584.
High soluble endoglin levels do not induce endothelial dysfunction in mouse - High soluble endoglin levels do not induce endothelial dysfunction in mouse
Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P. PLoS One. 2015 Mar 13;10(3):e0119665.
Persistent urinary podocyte loss following preeclampsia may reflect subclinical - Persistent urinary podocyte loss following preeclampsia may reflect subclinical
White WM, Garrett AT, Craici IM, Wagner SJ, Fitz-Gibbon PD, Butters KA, Brost BC, Rose CH, Grande JP, Garovic VD. PLoS One. 2014 Mar 24;9(3):e92693.
A phase I trial and pharmacokinetic study of sorafenib in children with - A phase I trial and pharmacokinetic study of sorafenib in children with
Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM. Clin Cancer Res. 2012 Nov 1;18(21):6011-22.
Plasma concentrations of soluble endoglin versus standard evaluation in patients - Plasma concentrations of soluble endoglin versus standard evaluation in patients
Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, Thadhani RI, Karumanchi SA. PLoS One. 2012;7(10):e48259.
MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce - MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce
Kaitu'u-Lino TJ, Palmer K, Tuohey L, Ye L, Tong S. PLoS One. 2012;7(6):e39864.
Phase I and pharmacokinetic study of sunitinib in pediatric patients with - Phase I and pharmacokinetic study of sunitinib in pediatric patients with
Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM. Clin Cancer Res. 2011 Aug 1;17(15):5113-22.
Prognostic significance of the angiogenic factors angiogenin, endoglin and - Prognostic significance of the angiogenic factors angiogenin, endoglin and
Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stoblen F, Lichtenegger W, Sehouli J, Kummel S. Anticancer Res. 2011 Aug;31(8):2651-5.
Circulating soluble endoglin levels in pregnant women in Cameroon and - Circulating soluble endoglin levels in pregnant women in Cameroon and
Silver KL, Conroy AL, Leke RG, Leke RJ, Gwanmesia P, Molyneux ME, Taylor DW, Rogerson SJ, Kain KC. PLoS One. 2011;6(9):e24985.
Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor - Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor
Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M. PLoS One. 2010 Oct 11;5(10):e13263.